Zobrazeno 71 - 80
of 334
pro vyhledávání: '"Jochen K. Lennerz"'
Autor:
Stephanie E. Weissinger, N. Zeke Georgantas, Julia C. Thierauf, Rebecca Pellerin, Emma Gardecki, Stephanie Kühlinger, Lauren L. Ritterhouse, Peter Möller, Jochen K. Lennerz
Publikováno v:
Laboratory Investigation. 103:100062
Autor:
Harshabad Singh, Kristen E. Lowder, Kevin Kapner, Ronan J. Kelly, Hui Zheng, Nadine J. McCleary, Thomas A. Abrams, Jennifer A. Chan, Eileen M. Regan, Samuel J. Klempner, Alison M. Hannigan, Lauren K. Brais, Elizabeth A. Andrews, Matthew B. Yurgelun, James M. Cleary, Douglas A. Rubinson, Lauren L. Ritterhouse, Garrett E. Maron, Andrew J. Aguirre, Lu Tan, Pan Du, Jeffrey A. Meyerhardt, Emma Gardecki, Jochen K. Lennerz, Shidong Jia, Brian M. Wolpin, Peter C. Enzinger
Publikováno v:
Cancer Research. 83:CT155-CT155
Introduction: Preclinical studies suggest cooperativity between blocking the human epidermal growth factor receptor 2 (HER2) and the vascular endothelial growth factor (VEGF) pathways in gastroesophageal adenocarcinomas (GEAs). Methods:Patients with
Autor:
Mihir Gupta, Joseph Bradley, Elie Massaad, Evan Burns, Deborah Forst, Daniel P. Cahill, Frederick George Barker, Justin Jordan, Jorg Dietrich, Jochen K. Lennerz, Brian V. Nahed, Bob S. Carter, Ganesh Shankar
Publikováno v:
Neurosurgery. 69:67-67
Autor:
Alice T. Shaw, Jochen K. Lennerz, Rebecca S. Heist, Justin F. Gainor, Kelly Goodwin, Andrew Do, Philicia Moonsamy, Ibiayi Dagogo-Jack, Aaron N. Hata, Subba R. Digumarthy, Inga T. Lennes, Zofia Piotrowska, Kristin Price, Sara Stevens, Alona Muzikansky, Jessica J. Lin, Lecia V. Sequist
Publikováno v:
Journal of Thoracic Oncology. 16:850-859
Introduction Capmatinib is approved for MET exon 14–altered NSCLC on the basis of activity in targeted therapy–naive patients. We conducted a phase 2 study to assess the efficacy of capmatinib in patients previously treated with a MET inhibitor.
Autor:
Islam Baiev, Jochen K. Lennerz, Lesli A. Kiedrowski, Mohammed Usman Syed, Chendi Li, Rebecca S. Heist, Samuel J. Klempner, Dejan Juric, Aaron N. Hata, Mustafa Sakhi, Katerina A. Fella, Ryan B. Corcoran, Alexa G. Michel, Justin F. Gainor, Junbing Zhang, Liron Bar-Peled, Jessica J. Lin, Meagan B. Ryan, Noritaka Tanaka, Giulia Siravegna
Publikováno v:
Cancer Discovery. 11:1913-1922
Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510 (sotorasib), have demonstrated efficacy in KRASG12C-mutant cancers, including non–small cell lung cancer (NSCLC). However, mechanisms underlying clinical acquired resista
Autor:
Behzad Salari, Lyn M. Duncan, Kevin S. Emerick, Jochen K. Lennerz, Eric H. Holbrook, Ruth K. Foreman
Publikováno v:
Journal of Cutaneous Pathology. 48:948-953
Melanosis, clinically presenting as a benign macular hyperpigmentation, consists of increased pigmentation (melanotic or melanocytic) either in the mucosal epithelial cells or as subepithelial pigment-laden macrophages. On the other hand, primary sin
Autor:
G. Petur Nielsen, Julio A. Diaz-Perez, Yin P Hung, Jochen K. Lennerz, Kevin A. Raskin, Miriam A. Bredella, A. John Iafrate, Valentina Nardi, Adam S. Fisch, Andrew E. Rosenberg, Santiago A. Lozano-Calderon
Publikováno v:
Histopathology. 78:849-856
Aims Simple bone cysts are benign intramedullary tumours primarily involving the long bones in skeletally immature individuals. Several mechanisms have been proposed for their pathogenesis. Although the diagnosis is typically straightforward, the int
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Vishwajith Sridharan, Azfar Neyaz, Abhijit Chogule, Islam Baiev, Stephanie Reyes, Emily G. Barr Fritcher, Jochen K. Lennerz, William Sukov, Benjamin Kipp, David T. Ting, Vikram Deshpande, Lipika Goyal
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(24)
Purpose: Selective FGFR inhibitors are effective against cholangiocarcinomas that harbor gene alterations in FGFR2. Clinical trials suggest that expression of wild-type FGFR mRNA can predict sensitivity to FGFR inhibitors, but this biomarker has not
Autor:
Dora Dias-Santagata, Rebecca S Heist, Adam Z Bard, Annacarolina F L da Silva, Ibiayi Dagogo-Jack, Valentina Nardi, Lauren L Ritterhouse, Laura M Spring, Nicholas Jessop, Alexander A Farahani, Mari Mino-Kenudson, Jill Allen, Lipika Goyal, Aparna Parikh, Joseph Misdraji, Ganesh Shankar, Justin T Jordan, Maria Martinez-Lage, Matthew Frosch, Timothy Graubert, Amir T Fathi, Gabriela S Hobbs, Robert P Hasserjian, Noopur Raje, Jeremy Abramson, Joel H Schwartz, Ryan J Sullivan, David Miller, Mai P Hoang, Steven Isakoff, Amy Ly, Sara Bouberhan, Jaclyn Watkins, Esther Oliva, Lori Wirth, Peter M Sadow, William Faquin, Gregory M Cote, Yin P Hung, Xin Gao, Chin-Lee Wu, Salil Garg, Miguel Rivera, Long P Le, A John Iafrate, Dejan Juric, Ephraim P Hochberg, Jeffrey Clark, Aditya Bardia, Jochen K Lennerz
Publikováno v:
The oncologist. 27(11)
Background Precision oncology relies on molecular diagnostics, and the value-proposition of modern healthcare networks promises a higher standard of care across partner sites. We present the results of a clinical pilot to standardize precision oncolo